Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year High at $45.12

Shares of Twist Bioscience Co. (NASDAQ:TWSTGet Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $45.12 and last traded at $45.10, with a volume of 110433 shares traded. The stock had previously closed at $42.37.

Analyst Ratings Changes

TWST has been the subject of a number of research analyst reports. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and boosted their target price for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Barclays boosted their price objective on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Evercore ISI increased their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Robert W. Baird lifted their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Scotiabank upped their price objective on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $42.50.

Get Our Latest Stock Analysis on TWST

Twist Bioscience Stock Up 0.5 %

The company has a market cap of $2.82 billion, a PE ratio of -14.39 and a beta of 1.64. The company has a 50-day moving average of $34.94 and a 200-day moving average of $32.65.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. During the same period in the previous year, the firm earned ($1.06) EPS. The business’s revenue for the quarter was up 25.1% compared to the same quarter last year. As a group, equities analysts predict that Twist Bioscience Co. will post -3.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 4,163 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $154,572.19. Following the transaction, the chief executive officer now owns 509,986 shares in the company, valued at approximately $18,935,780.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Emily M. Leproust sold 4,163 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $154,572.19. Following the completion of the sale, the chief executive officer now directly owns 509,986 shares of the company’s stock, valued at approximately $18,935,780.18. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Patrick John Finn sold 2,174 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the completion of the transaction, the chief operating officer now directly owns 176,206 shares in the company, valued at $5,307,324.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,415 shares of company stock worth $614,504. Insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its holdings in Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock valued at $1,103,000 after purchasing an additional 2,292 shares during the period. Magnetar Financial LLC purchased a new position in shares of Twist Bioscience during the 1st quarter valued at $389,000. PEAK6 Investments LLC grew its stake in shares of Twist Bioscience by 20.7% during the 1st quarter. PEAK6 Investments LLC now owns 14,000 shares of the company’s stock worth $480,000 after acquiring an additional 2,400 shares during the period. American International Group Inc. grew its stake in shares of Twist Bioscience by 0.8% during the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares during the period. Finally, Edgestream Partners L.P. purchased a new stake in Twist Bioscience in the 1st quarter worth about $242,000.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Stories

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.